Literature DB >> 1313690

Effects of cyclosporin A and a non-immunosuppressive analogue, O-acetyl cyclosporin A, upon the growth of parent and multidrug resistant human lung cancer cells in vitro.

P R Twentyman1, K A Wright, H M Wallace.   

Abstract

We have studied the ability of cyclosporin A (CsA) and a non-immunosuppressive analogue, O-acetyl cyclosporin A (OACsA, B3-243) to inhibit the growth of human lung cancer cells in vitro. Using continuous drug exposure and the MTT colorimetric assay to determine cell growth we found that CsA produced partial growth inhibition at doses ranging from 0.5 to 3.0 micrograms ml-1 (0.4-2.4 microM). At progressively higher doses, complete growth inhibition and in situ cell lysis were seen. The P-glycoprotein expressing multidrug resistant (MDR) variant H69/LX4 of the small cell line H69/P was less sensitive to cyclosporins than the parent line, but this was not true of the non-P-glycoprotein expressing MDR variants of large cell line COR-L23 or adenocarcinoma line MOR. Sensitivity to OACsA was approximately 2-fold higher than that to CsA in most of the lines although not in the most sensitive line, COR-L88. Even in COR-L88, exposed to CsA or OACsA for 24 h, clonogenic cell survival was reduced only to 50%. There was no reduction in polyamine content of COR-L23 or COR-L88 cells following 48 h of exposure to CsA or OACsA. The effects on cell growth could not be inhibited by the addition of exogenous putrescine, nor could they be enhanced by the addition of alpha-difluoromethylorthinine. It does not appear therefore that inhibition of polyamine synthesis is the basis of the observed growth inhibition.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1313690      PMCID: PMC1977618          DOI: 10.1038/bjc.1992.68

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  35 in total

1.  Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein.

Authors:  B M Foxwell; A Mackie; V Ling; B Ryffel
Journal:  Mol Pharmacol       Date:  1989-10       Impact factor: 4.436

2.  Treatment of Sézary syndrome with cyclosporin A.

Authors:  L Puttick; A Pollock; E Fairburn
Journal:  J R Soc Med       Date:  1983-12       Impact factor: 5.344

3.  Enhancement of anthracycline growth inhibition in parent and multidrug-resistant Chinese hamster ovary cells by cyclosporin A and its analogues.

Authors:  S K Chambers; W N Hait; B M Kacinski; S R Keyes; R E Handschumacher
Journal:  Cancer Res       Date:  1989-11-15       Impact factor: 12.701

4.  Inhibition of T lymphocyte activation by cyclosporin A: interference with the early activation of plasma membrane phospholipid metabolism.

Authors:  M Szamel; P Berger; K Resch
Journal:  J Immunol       Date:  1986-01       Impact factor: 5.422

5.  Reduced cyclosporin accumulation in multidrug-resistant cells.

Authors:  H Goldberg; V Ling; P Y Wong; K Skorecki
Journal:  Biochem Biophys Res Commun       Date:  1988-04-29       Impact factor: 3.575

6.  Reversal of drug-resistance by cyclosporin-A in a patient with acute myelocytic leukaemia.

Authors:  P Sonneveld; K Nooter
Journal:  Br J Haematol       Date:  1990-06       Impact factor: 6.998

7.  Amplification and expression of mdr1 gene in a multidrug resistant variant of small cell lung cancer cell line NCI-H69.

Authors:  J G Reeve; P H Rabbitts; P R Twentyman
Journal:  Br J Cancer       Date:  1989-09       Impact factor: 7.640

8.  The MTT assay underestimates the growth inhibitory effects of interferons.

Authors:  S A Jabbar; P R Twentyman; J V Watson
Journal:  Br J Cancer       Date:  1989-10       Impact factor: 7.640

9.  Establishment and characterisation of cell lines from patients with lung cancer (predominantly small cell carcinoma).

Authors:  H Baillie-Johnson; P R Twentyman; N E Fox; G A Walls; P Workman; J V Watson; N Johnson; J G Reeve; N M Bleehen
Journal:  Br J Cancer       Date:  1985-10       Impact factor: 7.640

10.  Effects of cyclosporin A on growth and polyamine metabolism of MOLT-4 T-lymphoblastic leukaemia cells.

Authors:  G McLachlan; A W Thomson; H M Wallace
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

View more
  5 in total

1.  Relative sensitivity of undifferentiated and cyclic adenosine 3',5'-monophosphate-induced differentiated neuroblastoma cells to cyclosporin A: potential role of beta-amyloid and ubiquitin in neurotoxicity.

Authors:  A Kumar; A R Hovland; F G La Rosa; W C Cole; J E Prasad; K N Prasad
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-02       Impact factor: 2.416

2.  In vitro and in vivo chemosensitizing effect of cyclosporin A on an intrinsic multidrug-resistant rat colon tumour.

Authors:  W Van de Vrie; E E Gheuens; N M Durante; E A De Bruijn; R L Marquet; A T Van Oosterom; A M Eggermont
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

3.  Relationship between P-glycoprotein expression and cyclosporin A in kidney. An immunohistological and cell culture study.

Authors:  R García del Moral; F O'Valle; M Andújar; M Aguilar; M A Lucena; J López-Hidalgo; C Ramírez; M T Medina-Cano; D Aguilar; M Gómez-Morales
Journal:  Am J Pathol       Date:  1995-02       Impact factor: 4.307

Review 4.  Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

Authors:  D J Booser; G N Hortobagyi
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

5.  Growth inhibition of human gastrointestinal cancer cells by cyclosporin A.

Authors:  M Piontek; R Porschen
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.